Mary Anne Ost, MD
Geriatric Medicine · West Grove, PANPI 1740249697
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 25.5% of the total. Among geriatric medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Amgen$613
- Pfizer$371
- AbbVie$371
- GSK$215
- plus $712 from 18 others
What the payments were for
- Food & beverage$4,39297%
- Education$1143%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $1,148 |
| Novo Nordisk | 89 | $1,077 |
| Amgen | 46 | $613 |
| Pfizer | 32 | $371 |
| AbbVie | 20 | $371 |
| GSK | 14 | $215 |
| Astellas Pharma US Inc | 10 | $209 |
| Johnson & Johnson | 8 | $105 |
| Novartis | 2 | $41 |
| Exact Sciences | 2 | $40 |
| Boston Scientific | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Tactile Systems Technology Inc | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| SNAP Diagnostics LLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Linus Health, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,506 in reported general payments places this provider in the 90th percentile of 217 geriatric medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 125 | $68,871 |
| OzempicSemaglutide | 18 | $34,394 |
| RybelsusSemaglutide | 18 | $34,312 |
| XareltoRivaroxaban | 29 | $28,752 |
| TrulicityDulaglutide | 18 | $23,370 |
| FarxigaDapagliflozin Propanediol | 22 | $22,998 |
| JanuviaSitagliptin Phosphate | 27 | $22,530 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $18,616 |
| MyrbetriqMirabegron | 16 | $16,961 |
| Rosuvastatin Calcium | 532 | $9,894 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $6,777 |
| Metoprolol Succinate | 225 | $5,281 |
| Serevent DiskusSalmeterol Xinafoate | 12 | $5,001 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,592 |
| Levothyroxine Sodium | 271 | $3,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $371 | $68,871125 claims |
| Novo NordiskOzempic, Rybelsus | $1,077 | $68,70636 claims |
| Johnson & JohnsonXarelto | $105 | $28,75229 claims |
| AstraZenecaFarxiga | $1,148 | $22,99822 claims |
| GSKTrelegy Ellipta | $215 | $18,61626 claims |
| Astellas Pharma US IncMyrbetriq | $209 | $16,96116 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $39 | $6,77717 claims |
| AbbVieSynthroid | $371 | $2,76337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 217 geriatric medicine providers in Pennsylvania.
Other geriatric medicine in West Grove
- Richard StefanacciPhiladelphia$146K
- James LinErie$73K
- Adele TowersPittsburgh$29K
- Michele ZaworaPhiladelphia$21K
- Daniel HaimowitzLevittown$15K
- Robert PearlsteinPlymouth Meeting$15K
- Seth CarterErie$14K
- Moushumi KunduHanover$12K
- Jason KarlawishPhiladelphia$11K
- Mario CornacchioneAllentown$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.